Harini Jalagani, MD
Endocrinology, Diabetes & Metabolism · Cartersville, GANPI 1336111558
Payments from drug & device makers
Across 71 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$215
- Medtronic$212
- Abbott$111
- Lilly USA, LLC$87
- Corcept Therapeutics$77
- Novo Nordisk$59
- plus $736 from 27 others
What the payments were for
- Food & beverage$1,28686%
- Education$926%
- Gifts$1198%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 6 | $215 |
| Medtronic(2 entities) | 9 | $212 |
| Abbott | 4 | $111 |
| Lilly USA, LLC | 5 | $87 |
| Corcept Therapeutics | 4 | $77 |
| Novo Nordisk | 3 | $59 |
| Insulet Corporation | 3 | $53 |
| Sequel Med Tech, LLC | 2 | $53 |
| Antares Pharma, Inc. | 3 | $51 |
| Tandem Diabetes Care, Inc. | 3 | $49 |
| Amgen(2 entities) | 3 | $49 |
| Recordati_rare_diseases_inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Novartis | 1 | $29 |
| IBSA Pharma Inc. | 2 | $28 |
| BETA Bionics, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $22 |
| Bigfoot Biomedical Inc | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Chiasma, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Intuity Medical Inc | 1 | $16 |
| AbbVie | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Bayer | 1 | $12 |
How this compares
$1,497 in reported general payments places this provider in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $382,890 |
| MounjaroTirzepatide | 229 | $371,754 |
| JardianceEmpagliflozin | 189 | $229,785 |
| TrulicityDulaglutide | 79 | $114,506 |
| TradjentaLinagliptin | 94 | $101,165 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 353 | $60,253 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $53,810 |
| FarxigaDapagliflozin Propanediol | 35 | $48,248 |
| Novolog FlexpenInsulin Aspart | 151 | $46,919 |
| RybelsusSemaglutide | 30 | $44,898 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $41,621 |
| Humalog Kwikpen U-100Insulin Lispro | 99 | $34,896 |
| SynthroidLevothyroxine Sodium | 343 | $34,201 |
| JanuviaSitagliptin Phosphate | 30 | $30,823 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $28,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $87 | $516,208409 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $59 | $443,300278 claims |
| AstraZenecaFarxiga | $16 | $48,24835 claims |
| AbbVieSynthroid | $16 | $34,201343 claims |
| MerckJanuvia | $13 | $30,82330 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $6,86740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Cartersville
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.